Axogen Inc. (AXGN) got the green light from the FDA on Wednesday for its Biologics License Application for Avance, an acellular nerve scaffold designed to repair peripheral nerve damage. The approval covers sensory, mixed, and motor nerve discontinuities in patients from one month old through adulthood.

Here's why this matters: Traditional nerve repair often requires surgeons to harvest healthy nerve tissue from somewhere else in the patient's body—creating a second surgical site with its own set of complications and recovery issues. Avance sidesteps that problem entirely.

The product is what's called an acellular nerve allograft. It's made from nerve tissue donated by deceased donors, then specially processed to strip away cells while keeping the natural structural framework intact. That framework acts as a scaffold, guiding nerve regeneration across the gap without requiring the patient to sacrifice healthy tissue elsewhere.

The Approval Pathway

The FDA granted approval through two different routes. For sensory nerve gaps of 25mm or less, the approval was based on standard clinical data showing improvement in static two-point discrimination—a measure of how well patients can distinguish between two nearby points of touch.

For larger sensory gaps (greater than 25mm) and for mixed and motor nerve repairs, the FDA used its Accelerated Approval pathway. This means the agency found enough evidence to reasonably predict clinical benefit based on how the product performed in smaller sensory nerve gaps, given the similarities in how these injuries develop and how the treatment should work. However, continued approval for these broader indications depends on Axogen completing confirmatory studies that verify the clinical benefits.

What's Next

The newly licensed version of Avance won't hit the market immediately. Commercial availability is expected in early Q2 2026. In the meantime, the product remains available under the existing tissue regulatory framework.

The approval comes after a slight delay. Back in August, the FDA classified Axogen's response to an information request as a Major Amendment to the Biologics License Application. That response included substantial new manufacturing and facility data the agency hadn't previously reviewed, which pushed back the timeline by about three months.

Strong Financial Performance

Axogen has been executing well on the business side. The company reported third-quarter revenue of $60.1 million, up 23.5% year over year and beating analyst expectations of $56.81 million. Adjusted earnings came in at 12 cents per share, crushing the consensus estimate of 7 cents.

Management raised its 2025 revenue guidance to reflect at least 19% growth, which translates to $222.8 million for the year. The company expects gross margins between 73% and 75%, though that range includes some one-time costs tied to the Avance BLA approval—roughly a 1% hit to gross margin, or about $2 million. Axogen also reiterated that it expects positive net cash flow for the full year.

Investors clearly liked what they heard. Axogen shares jumped 18.78% to $31.01, reaching a new 52-week high following the FDA announcement.